Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.69 |
| ▸ | DRD3 | P35462 | 9/20 | 0.69 |
| ▸ | HTR2C | P28335 | 6/20 | 0.59 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30809964 | 1.00 | DRD2 (0.69) | DRD2DRD3HTR2CSLC18A3SIGMAR1 | |
| SCHEMBL4875328 | 0.89 | DRD2 (0.67) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL31523251 | 0.85 | DRD2 (0.73) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| Tert-Butyl Formate SCHEMBL27635042 | 0.84 | DRD3 (0.51) | DRD2DRD3HTR2CSLC18A3SIGMAR1 | |
| SCHEMBL14869628 | 0.84 | DRD2 (0.76) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL2227921 | 0.84 | DRD2 (0.71) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL4071635 | 0.82 | DRD2 (0.59) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL28728225 | 0.82 | DRD2 (0.59) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL31210148 | 0.82 | DRD2 (0.73) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL26692355 | 0.82 | DRD2 (0.73) | DRD2DRD3CYP2D6TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104926801-B | Substituted azetidine analog derivative, the pharmaceutical composition containing it and its application in antitumor | 浙江大学 | 2019-06-04 | — | — | CN | claimed |
| EP-4731223-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | Universitat De Barcelona (ES) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024261340-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | UNIVERSITAT DE BARCELONA (ES) | 2024-12-26 | — | — | WO | disclosed |
| CN-118146234-A | 6,5,7,6-Tetracyclic derivatives, preparation method and application thereof | 浙江我武翼方药业有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024114672-A1 | 6,5,7,6-TETRACYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江我武翼方药业有限公司 | 2024-06-06 | — | — | WO | disclosed |
| EP-3423436-B1 | PYRIDINYLMETHYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| EP-3083601-B1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-09-09 | — | — | EP | disclosed |
| US-10730850-B2 | Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-04 | — | — | US | disclosed |
| CN-105849096-B | Piperidine derivatives having multimodal activity against pain | 埃斯蒂文制药股份有限公司 | 2019-11-29 | — | — | CN | disclosed |
| US-10336729-B2 | 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| US-20070238723-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | GOBLE STEPHEN D | 2007-10-11 | — | — | US | disclosed |
| US-20070238723-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | GOBLE STEPHEN D | 2007-10-11 | — | — | US | disclosed |
| US-20070238723-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | GOBLE STEPHEN D | 2007-10-11 | — | — | US | disclosed |
| US-20060069088-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1615699-A2 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | Merck & Co., Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040220171-A1 | 1-Aroyl-piperidinyl benzamidines | AVENTIS PHARMACEUTICALS INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004092124-A2 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-1278732-A1 | 1-AROYL-PIPERIDINYL BENZAMIDINES | Aventis Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020045613-A1 | 1-aroyl-piperidinyl benzamidines | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001081310-A1 | 1-AROYL-PIPERIDINYL BENZAMIDINES | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220171-A1 | 1-Aroyl-piperidinyl benzamidines | TPSAB1, TPSB2, CMA1 | DRD2 2633/4885DRD3 2646/4885HTR2C 370/4885 |
| US-20060069088-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | CCR1, CCR2, CCRL2 | DRD2 2005/4885DRD3 2262/4885HTR2C 306/4885 |
| US-20020045613-A1 | 1-aroyl-piperidinyl benzamidines | TPSAB1, TPSB2, CMA1 | DRD2 2633/4885DRD3 2646/4885HTR2C 370/4885 |
| US-10336729-B2 | 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | AOC3, AOC2, CBR3 | DRD2 4335/4885DRD3 2251/4885HTR2C 2986/4885 |
| US-20070238723-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | CCR1, CCR2, CCRL2 | DRD2 2005/4885DRD3 2262/4885HTR2C 306/4885 |
| US-10730850-B2 | Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | AOC3, XDH, CYP3A43 | DRD2 3596/4885DRD3 773/4885HTR2C 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.